AU2020387399A1 - Methods of treating warm autoimmune hemolytic anemia using anti-FcRn antibodies - Google Patents

Methods of treating warm autoimmune hemolytic anemia using anti-FcRn antibodies Download PDF

Info

Publication number
AU2020387399A1
AU2020387399A1 AU2020387399A AU2020387399A AU2020387399A1 AU 2020387399 A1 AU2020387399 A1 AU 2020387399A1 AU 2020387399 A AU2020387399 A AU 2020387399A AU 2020387399 A AU2020387399 A AU 2020387399A AU 2020387399 A1 AU2020387399 A1 AU 2020387399A1
Authority
AU
Australia
Prior art keywords
antibody
antigen
binding fragment
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020387399A
Other languages
English (en)
Inventor
Christine Morel COQUERY
Jonathon Andrew KLUFT
William Thomas SYMONDS III
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunovant Sciences GmbH
Original Assignee
Immunovant Sciences GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunovant Sciences GmbH filed Critical Immunovant Sciences GmbH
Publication of AU2020387399A1 publication Critical patent/AU2020387399A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2020387399A 2019-11-19 2020-11-18 Methods of treating warm autoimmune hemolytic anemia using anti-FcRn antibodies Abandoned AU2020387399A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962937395P 2019-11-19 2019-11-19
US62/937,395 2019-11-19
PCT/US2020/061028 WO2021101975A1 (en) 2019-11-19 2020-11-18 Methods of treating warm autoimmune hemolytic anemia using anti-fcrn antibodies

Publications (1)

Publication Number Publication Date
AU2020387399A1 true AU2020387399A1 (en) 2022-05-19

Family

ID=73854886

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020387399A Abandoned AU2020387399A1 (en) 2019-11-19 2020-11-18 Methods of treating warm autoimmune hemolytic anemia using anti-FcRn antibodies

Country Status (10)

Country Link
US (1) US20230049011A1 (cg-RX-API-DMAC7.html)
EP (1) EP4061486A1 (cg-RX-API-DMAC7.html)
JP (1) JP7722991B2 (cg-RX-API-DMAC7.html)
CN (1) CN114728180A (cg-RX-API-DMAC7.html)
AU (1) AU2020387399A1 (cg-RX-API-DMAC7.html)
CA (1) CA3157797A1 (cg-RX-API-DMAC7.html)
IL (1) IL292889A (cg-RX-API-DMAC7.html)
MX (1) MX2022005862A (cg-RX-API-DMAC7.html)
TW (1) TW202132346A (cg-RX-API-DMAC7.html)
WO (1) WO2021101975A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117693523A (zh) * 2021-08-13 2024-03-12 舒泰神(北京)生物制药股份有限公司 特异性识别fcrn的抗体及其用途
AU2023281650A1 (en) 2022-05-30 2024-10-17 Hanall Biopharma Co., Ltd. Anti-fcrn antibody or antigen binding fragment thereof with improved stability
JP2025528527A (ja) * 2022-09-06 2025-08-28 イミュノバント・サイエンシズ・ゲーエムベーハー 抗FcRN抗体を用いたグレーブス病の治療方法
WO2026136830A1 (en) * 2024-12-20 2026-06-25 Paragon Therapeutics, Inc. Anti-fcrn antibodies and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4241852A3 (en) 2014-04-30 2023-11-15 Hanall Biopharma Co., Ltd. Antibody binding to fcrn for treating autoimmune diseases
US10336825B2 (en) * 2014-04-30 2019-07-02 Hanall Biopharma Co., Ltd. Antibody binding to FcRn for treating autoimmune diseases
JP6853178B2 (ja) * 2015-01-30 2021-03-31 モメンタ ファーマシューティカルズ インコーポレイテッド FcRn抗体およびその使用方法
CA3022547A1 (en) * 2015-05-12 2016-11-17 Syntimmune, Inc. Humanized affinity matured anti-fcrn antibodies
BR112019001806A2 (pt) * 2016-07-29 2019-05-07 Momenta Pharmaceuticals, Inc. anticorpos para fcrn e métodos de uso dos mesmos
EP3762027A4 (en) * 2018-02-13 2022-06-15 The Brigham & Women's Hospital, Inc. THERAPEUTIC FCRN-BASED BISPECIFIC MONOCLONAL ANTIBODIES

Also Published As

Publication number Publication date
CA3157797A1 (en) 2021-05-27
MX2022005862A (es) 2022-06-23
IL292889A (en) 2022-07-01
CN114728180A (zh) 2022-07-08
US20230049011A1 (en) 2023-02-16
TW202132346A (zh) 2021-09-01
WO2021101975A1 (en) 2021-05-27
EP4061486A1 (en) 2022-09-28
JP7722991B2 (ja) 2025-08-13
JP2023502398A (ja) 2023-01-24
KR20220100880A (ko) 2022-07-18

Similar Documents

Publication Publication Date Title
JP7489978B2 (ja) 抗FcRn抗体を用いたグレーブス眼症の治療方法
EP3137504B1 (en) Antibody binding to fcrn for treating autoimmune diseases
AU2007238677B2 (en) Use of IL-I antibodies for treating ophthalmic disorders
JP7722991B2 (ja) 抗fcrn抗体を用いた温熱自己免疫性溶血性貧血の治療方法
US20260078189A1 (en) Methods of treating chronic inflammatory demyelinating polyneuropathy using anti-fcrn antibodies
US20260078188A1 (en) Methods of treating graves’ disease using anti-fcrn antibodies
HK40068854A (en) Methods of treating warm autoimmune hemolytic anemia using anti-fcrn antibodies
HK40121539A (en) Methods of treating chronic inflammatory demyelinating polyneuropathy using anti-fcrn antibodies
HK40124168A (en) Methods of treating graves' disease using anti-fcrn antibodies
HK40058301B (en) Methods of treating graves' ophthalmopathy using anti-fcrn antibodies
HK40058301A (en) Methods of treating graves' ophthalmopathy using anti-fcrn antibodies

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period